CONGRESS PRESENTATIONS

CONGRESS PRESENTATIONS

CROI 2021

Conference on Retroviruses and Opportunistic Infections

March 6 - 10, 2021
Virtual

  • Dolutegravir

    Albano JD, et al.

    The antiretroviral pregnancy registry: 30 years of monitoring for congenital anomalies. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Bansi-Matharu L, et al.

    Association between newer antiretrovirals and increase in body mass index in RESPOND. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Benson P, et al.

    Switching to DTG/3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) through 96 weeks: Subgroup analyses from the TANGO study. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Llibre JM, et al.

    Inflammatory and atherogenesis markers 148 weeks post-switch to dtg+rpv in sword-1/-2. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Neesgaard B, et al.

    Association between integrase inhibitors (INSTIs) and cardiovascular disease (CVD). Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Orkin C, et al.

    Durable efficay of DTG+3TC in GEMINI 1& 2: Year 3 sub-group analyses. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

  • Cabotegravir

    Benn P, et al.

    Long-acting cabotegravir+rilpivirine in older adults: pooled phase 3 week 48 results. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Benn P, et al.

    Renal/bone outcomes after long-acting cabotegravir + rilpivirine in ATLAS + ATLAS-2M. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Han K, et al.

    Cabotegravir PPK simulation to inform Q2M strategies following dosing interruptions. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Jaeger H, et al.

    Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Patel P, et al.

    Weight and lipid changes in phase 3 cabotegravir and rilpivirine long-acting trials. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Rossenu S, et al.

    PopPK modeling of Q2M IM RPV LA for managing dosing interruptions in HIV-1 patients. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

  • Fostemsavir

    Rose B, et al.

    Reduced susceptibility to temsavir is not linked to IBA or MVC resistance. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

  • Disease State

    Berko J, et al.

    RCT of an online mental health intervention among older PLWH during COVID-19 pandemic. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Oral Presentation.

  • Investigational Products

    Jeffrey JL, et al.

    GSK3640254 is a novel maturation inhibitor with an optimized virology profile. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Science Spotlight.

    Spinner C, et al.

    Phase IIa proof-of-concept trial of next-generation maturation inhibitor GSK3640254. Presented at CROI 2021, March 6-10, 2021, Virtual Event. Oral Presentation.

This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

My MSL

Enter zip code to find your MSL contact.